ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 13, 2016--
BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company
with a focus on pluripotent stem cell technology, today announced that
Adi Mohanty, Co-Chief Executive Officer, will be presenting at the BIO
Investor Forum on Wednesday, October 19, 2016, at 2:00 p.m. Pacific Time
/ 5:00 p.m. Eastern Time. The BIO Investor Forum is being held at the
Westin St. Francis Hotel in San Francisco.
The presentation will be webcast live and will also be available for
replay at the “Events & Presentations” page of the “Investors & Media”
section on BioTime’s website at http://www.biotimeinc.com/.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what we
believe to be the world’s premier collection of pluripotent cell assets.
The foundation of our core therapeutic technology platform is
pluripotent cells that are capable of becoming any of the cell types in
the human body. Pluripotent cells have potential application in many
areas of medicine with large unmet patient needs, including various
age-related degenerative diseases and degenerative conditions for which
there presently are no cures. Unlike pharmaceuticals that require a
molecular target, therapeutic strategies based on the use of pluripotent
cells are generally aimed at regenerating or replacing affected cells
and tissues, and therefore may have broader applicability than
In addition to the development of therapeutics, BioTime’s research and
other activities have resulted, over time, in the creation of other
subsidiaries that address other non-therapeutic market opportunities
such as cancer diagnostics, drug development and cell research products,
and mobile health software applications.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161013005488/en/
Source: BioTime, Inc.
EVC Group, Inc.
Gotham Communications, LLC